
August 11, 2022
Oncopeptides publishes Q2 report 2022
STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hemato...
Read more
Read more

August 11, 2022
Targovax ASA: Invitation to Targovax’s second quarter and first half 2022 presentation, Thursday 18 August
Oslo, Norway, 11 August 2022 – Targovax ASA (OSE: TRVX) will announce its second quarter and first half 2022 results on Thursday 18 August 2022. Targovax’s management will pre...
Read more
Read more

August 10, 2022
Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease
PHILADELPHIA, PA., AUGUST 10, 2022 – Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. ...
Read more
Read more

August 10, 2022
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022)
Appointment of P.J. Ramtin as Senior Vice President of Busines...
Read more
Read more

August 9, 2022
Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results And Clinical Program Updates
FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy
Data supporting ongoing evaluation of cold antibody pre-administ...
Read more
Read more

August 3, 2022
Pulmonx Reports Second Quarter 2022 Financial Results
Aug 2, 2022PDF Version
REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally...
Read more
Read more

July 27, 2022
InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation
Single Pivotal Phase 3 Trial to Support Filing of New Drug Application
Positive Phase 2 Efficacy and Safety Data for InRhythm Recently Highlighted as “Editor’s Pic...
Read more
Read more

July 26, 2022
Precirix and Eckert & Ziegler sign agreement on priority supply of the therapeutic radioisotope Actinium-225
Brussels, Belgium and Berlin, Germany, 26 July 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, and Eckert &...
Read more
Read more

July 20, 2022
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides’ Pepaxto
STOCKHOLM — July 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematolo...
Read more
Read more

July 15, 2022
BONESUPPORT HOLDING AB (PUBL) – PUBLISHES Q2 2022 INTERIM REPORT
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2022.STRONG SALES...
Read more
Read more